When we founded amofor more than six years ago, most of what we did lived in equations, theories, and model ideas. We believed that physical modeling could change how drug formulations are developed, making them faster and better, but in the early days it still felt like a promise.
2025 was the first year where that promise really began to show up in how our projects move through development.
Our Top 3 Business Milestones In 2025
1/ ASD formulations modeled by amofor are now on their way to patients
Several of our ASD projects have successfully passed late-stage development, and in 2026 we will see the first of these in-silico designed formulations on the market.
Some of these are part of cutting-edge therapies that many people are watching closely, in high-impact disease areas.
For us, that feels different from anything before.
We’ve done many “test us” projects where a client gives us an existing formulation to see how well our models match reality. That’s important, and it helped build trust. But working on a complex and novel formulation before approval, and then seeing that work carry through to late stage, is another level.
It shows that our predictions have been reliable enough to enable teams to move forward with confidence, scale up, and bring these formulations closer to patients.
2/ A major increase in clients using SOLCALC
If you’ve followed amofor for a while, you know that our SOLCALC software has always been at the core of what we do. It’s the place where we bring together physical models, data, PC-SAFT, and formulation decisions. For a long time, though, it was mainly used by scientists who already felt comfortable with thermodynamics or modeling.
This year, that started to shift.
We see a massive interest in the software and a lot more companies decided to buy the SOLCALC licence. They want these capabilities in-house, but also don’t want every user to become a thermodynamics specialist.
So we’ve started to put concrete steps in place to get there and improve that, i.e. simpler paths instead of open toolboxes. We’re building more guided workflows and cleaner graphical interfaces so users are less likely to make critical input mistakes.
We will not arrive at the point where you can ignore the underlying physics completely, and honestly, we probably never should be. But we are getting much closer to a SOLCALC version where a formulator can move through a project with clear, structured guidance and dedicated training sessions, even without being a modeling expert.
3/ The amofor team is growing
We’ve grown into a small group of people who bring different skills and perspectives: thermodynamics, software development, and deep understanding of pharmaceutical science.
This integrated expertise brings several benefits to our customers:
- We can now handle more complex projects in parallel and manage large projects even more efficiently.
- We can build advanced digital twins faster and tackle very specific problems, whether in novel pharmaceuticals or other industries.
- And maybe most importantly, we will continue to focus on our core values i.e. first-principles science, innovation, transparent communication, and flexibility.
amofor’s Biggest Scientific Advances In 2025
On the technical side, the biggest step forward was how we started to use large data sets to train and refine our models.
We brought in bigger, carefully curated collections of solubility and stability data and used them to improve how we fit parameters and describe intermolecular interactions. This had a huge impact as the quality of our fits improved by several orders of magnitude. The result is that we are now much better at predicting how APIs interact with polymers, particularly in complex, cutting-edge ASDs.
At the same time, we continued to build and publish with our valued partners. Together, we have made significant progress in advancing in silico formulation development and expanding the frontiers of pharmaceutical science. Here’s a quick look at some of our most exciting work!
Our 2025 publication highlights:
Spray-Drying Process Optimization and Modeling for an Inhaled Dry
Powder of 5‑Azacytidine for Treating Local and Metastatic Lung Cancer
Where Does amofor Stand In The ASD Landscape?
The picture after six years is quite different from where we started.
When we first talked about PC-SAFT and ASDs, it was often seen as a hyper specialist topic. Something you called an expert for when you had a tough corner case, not something you’d use in your normal formulation workflow.
Today, many of our clients already know what this type of modeling can do such as:
- picking polymers more rationally
- estimating stable drug load ranges
- making spray drying steps less trial-and-error
- getting clear shelf life estimations
We also see more companies mentioning similar modeling approaches in their own talks and publications or talking about each other about the amofor approach. For us it’s an important sign that we are a trusted partner when it comes to questions relating ASD formulation.
amofor Goals For 2026
Two key topics are already clear.
1/ Keep pushing the boundary of what we can predict
We want to answer more of the questions that formulators struggle with today, especially around ASDs. That includes making it normal to ask a model for an initial answer when a new ASD problem appears. Not just explaining why a release mechanism looks the way it does, but actually predicting full release curves
A big research focus here is taking a first step toward “no training data” predictions.
Right now, we need 5 solubility data points, and we’ll give you a very solid model. In the future, we’d like to add a layer on top of that: you start with only the chemical structures, the model gives you a first estimate of what might work, and then you refine with measurements when needed. This won’t replace good data. But it could make the very early stages of formulation faster and lower risk, especially when you’re screening many molecules at once.
The long-term vision is ambitious: being able to design a full ASD digitally first, with experiments acting as validation and fine-tuning rather than blind trial and error.
2/ More collaborations, more conferences
We already collaborate with several companies and work very closely with them on scientific questions. These long-term relationships are where many of our new ideas come from, rooted in real drug formulation problems.
In 2026, we’d like to deepen these collaborations and start a few new ones with larger pharma partners. So we encourage you to reach out if you are working on innovative drug formulation projects.
Next year, we also plan to be more present at pharmaceutical conferences, discuss these topics in person, and share more of what we do face to face.
Seasonal wishes
As the year comes to a close, we’d also like to take the opportunity to thank you for being an integral part of our journey.
We wish you a joyful holiday season!
Warm wishes,
The amofor team